RISK WATCHYahoo Finance • 1d ago
CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement DropYahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
Why CRMD Stock dropped -5.36% Today — RQD Quant Desk Flash
$5.39 -5.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.33
CorMedix Inc. (CRMD) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $443.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CRMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, CorMedix Inc. (NASDAQ: CRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $5.39 (-5.36% 1D, market cap $443.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CRMD ranks #172 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CRMD compare to KMDA and BLSM in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C- (59/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, KMDA (Kamada Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $444.4M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CRMD?
▼
Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.33 (-1.15%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 55.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE+0.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY CRMD SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 55.4% FCF Margin ($172.8M FCF) & 88.5% Gross Margin
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (25% of score)
SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$7.39+2.4% Next Q
67
Q2 (-2Q)Grade C+$7.57+5.7% Next Q
64
Q3 (-1Q)Grade C+$8.00-32.6% Next Q
62
CurrentGrade C-$5.39+0.2% Hist 90D α
59
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CRMD Bull Thesis Could Fail
Even with a 59/100 (C-) score, CRMD faces multiple-compression risk if 3.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 86.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($7.74) or 200D SMA ($7.67) invalidates the momentum regime and cuts Target Base ($5.41) toward Bear Floor ($4.22).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CRMD Stock dropped -5.36% Today — RQD Quant Desk Flash
CorMedix Inc. (CRMD) dropped -5.36% to $5.39, trading at 2% of its 52-week range ($5.63 – $13.02). Solid 88.5% gross margin (46% return on capital), mixed timing at 4x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 2% of its 52-week range ($5.63 – $13.02) with RSI-14 at 37.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.39 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 88.5% gross margin and $172.8M annual free cash flow.
Live CRMD Headlines & Catalysts
MARKET WIRESeeking Alpha • 1d ago
Cormedix Rezzayo label expansion under FDA review (CRMD:NASDAQ)Seeking Alpha report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Yahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
CATALYSTkalkine.ca • 1d ago
CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Storykalkine.ca report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
CorMedix (NASDAQ:CRMD) Reaches New 1-Year Low - Here's WhyMarketBeat report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
CATALYSTSimply Wall St • 1d ago
With EPS Growth And More, CorMedix (NASDAQ:CRMD) Makes An Interesting CaseSimply Wall St report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplantsStock Titan report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: Olympus (OtherOCPNF), IQVIA Holdings (IQV) and Cormedix (CRMD)The Globe and Mail report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 1d ago
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash PositionPARSIPPANY, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s
MARKET WIREBenzinga • 1d ago
CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325 million and $345 million
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CRMD Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.77%▼ SUPPORT BREAKDOWN
2026-11-03O $7.64H $7.64L $5.39C $5.39VOL 7.02M
RES: $8.32SUP: $6.35SMA50: $7.74SMA200: $7.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
-15.0%/yr Implied 5Y Growth
vs. +617.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on CRMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CRMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRMD)
Health Care Rank #172 of 1015
⚔️ KMDA vs CRMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CRMD vs. KMDA, BLSM, PRTA, PHAT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, CorMedix Inc. (CRMD) ranks #172 by composite RQD confidence (59/100, grade C-) and #462 by equity capitalization ($443.9M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CRMD
ACTIVE
CorMedix Inc. | C- | 59/100 | 3.7x | 88.5% | 45.5% | -5.36% | $443.9M | Benchmark Subject |
| KMDA Kamada Ltd. | D | 46/100 | — | — | — | -4.42% | $444.4M | /kmda-vs-crmd → |
| BLSM BlossomHill Therapeutics Inc. | D- | 42/100 | — | — | — | -9.67% | $437.0M | /blsm-vs-crmd → |
| PRTA Prothena Corporation plc | E | 23/100 | — | — | -35.0% | -2.12% | $434.8M | /prta-vs-crmd → |
| PHAT Phathom Pharmaceuticals Inc. | E | 33/100 | — | 87.1% | -35.0% | +3.05% | $466.6M | /phat-vs-crmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001410098 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), CorMedix Inc. (CRMD) reported GAAP revenue of $311.7M (+617.0% vs. FY2024 revenue of $43.5M , and +127.4% cumulative change since FY2023) , GAAP net income of $163.1M, operating cash flow of $175.0M, and free cash flow of $172.8M (+440.6% YoY). On the balance sheet, CRMD closed FY2025 with $826.1M in total assets against $0 in total debt (Altman Z-Score: 1.81, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $311.7M | $163.1M | $175.0M | $172.8M | $826.1M | — |
| FY2024 (FY) | 2024-12-31 | $43.5M | -$17.9M | -$50.6M | -$50.7M | $118.8M | — |
| FY2023 (FY) | 2023-12-31 | $137.1M | -$46.3M | -$38.4M | -$38.4M | — | — |
3. CRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, CorMedix Inc. (NASDAQ: CRMD) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $5.39 (-5.36% 1D, market cap $443.9M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, CRMD ranks #172 in composite RQD confidence.
How does CRMD compare to KMDA and BLSM in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRMD carries a Roarable C- (59/100 RQD), trailing P/E of 3.7x, gross margin of 88.5%, and ROIC of 45.5%. By comparison, KMDA (Kamada Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $444.4M) and BLSM (BlossomHill Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CRMD?
Per CRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001410098), CorMedix Inc. generated $311.7M in revenue (+617.0% YoY), $163.1M in net income, and $172.8M in free cash flow against $826.1M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CRMD trading relative to its 50-day, 200-day, and 52-week technical levels?
CRMD last traded at $5.39 (-5.36% on volume of 3,304,345 shares), positioning the stock -30.36% below its 50-day simple moving average ($7.74) and -29.73% below its 200-day simple moving average ($7.67). Across its 52-week range of $5.63 to $13.02, CRMD sits at the 0.0% percentile with a 14-day RSI of 37.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.72 to $6.06).
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ SEC XBRL & RQD VERIFIED
CRMD — CorMedix Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
CorMedix Inc. (CRMD) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $5.39 (-5.36% 1D, market capitalization $443.9M).
- Fundamental Cash Engine (16/20): Anchored by return on invested capital (ROIC) of 45.5%, gross margin of 88.5%, operating margin of 48.2%, and free cash flow yield of —.
- Whale 13F & Options Flow (4/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.81, Piotroski F-Score of 8/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
CorMedix Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The profile identifies the company by sector, industry, exchange, and market capitalization of $0.6B. Gross margin is reported at 88.5%, operating margin at 48.2%, and net margin at 52.3%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), CorMedix Inc. (CRMD) reported $311.7M in annual revenue (up from $43.5M in FY2024, +617.0% YoY) and $163.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($137.1M revenue, -$46.3M net income) through FY2025, CRMD scaled operating cash flow to $175.0M and free cash flow to $172.8M, backed by $826.1M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C- • RQD 59/100): Strong cash generator (88.5% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 16/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $5.63 – $13.02 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 3.7x trailing P/E and 3.0x EV/EBITDA against 48.2% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The one ripple the news wire does point to is reimbursement: the DaVita warning on 2027 DefenCath reimbursement implies that payer-side pricing decisions could transmit into the company's revenue, and an investor should monitor reimbursement announcements as the primary second-order channel.
- Key Question #1: Can CRMD sustain or expand its 48.2% operating margin and 45.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $311.7M and free cash flow of $172.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is CRMD's 3.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
CRMD Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for CorMedix Inc. (CRMD) • Click "Debate This Headline" to argue it in the Roar Pit below
🔴 RISK WATCH Yahoo Finance • 1d ago
CRMD Stock Hits Fresh 52-Week Low On DaVita’s Warning Of Sharp 2027 DefenCath Reimbursement Drop Yahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Cormedix Rezzayo label expansion under FDA review (CRMD:NASDAQ) Seeking Alpha report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? Yahoo Finance report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST kalkine.ca • 1d ago
CorMedix (NASDAQ: CRMD) Strengthens Its Commercial Growth Story kalkine.ca report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
CorMedix (NASDAQ:CRMD) Reaches New 1-Year Low - Here's Why MarketBeat report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Simply Wall St • 1d ago
With EPS Growth And More, CorMedix (NASDAQ:CRMD) Makes An Interesting Case Simply Wall St report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A weekly antifungal is under priority review to prevent fungal disease during stem-cell transplants Stock Titan report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
Analysts Offer Insights on Healthcare Companies: Olympus (OtherOCPNF), IQVIA Holdings (IQV) and Cormedix (CRMD) The Globe and Mail report covering CorMedix Inc. (CRMD) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CRMD Bull vs. Bear Conversation Board — What's Your Call at $5.39?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRMD 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $6.95 (+21.9%)
📌 Pinned Debate Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.
Picked up a starter position in CRMD in my $100K Virtual Cash book at $5.70. Reported FY 2025 operating income of $150.1M and ROIC of 45.5% show strong earnings power against a $595.5M market cap.. Trading inside a $5.63–$13.02 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.
RetailWhale_TX 🐂 BULL
@FadeTheHype Shorting a 4/20 institutional whale-flow stock at $5.70 is dangerous when funds are rotating into Health Care.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $4.79 (-16.0%)
Spot @ $5.70 The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.
Here is the bear case nobody on the bull side wants to address on CRMD: The stock hit a fresh 52-week low on a DaVita warning of a sharp 2027 DefenCath reimbursement drop.. At 3.7x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.